Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Giude to Best Web based Learning Stage - 2Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- 3Fossils unearthed in Morocco are first from little-understood period of human evolution
- 4Private sector revives the climate disaster database Trump tried to squash
- 5Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- UB professor shares his experience on almost becoming an astronaut
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Living Abroad: Social Inundation and Self-improvement
- When the moon hits your eye from your Orion ship up high, that's a 'mare'
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- The Electric Bicycle Americans Can Confide in 2024
- Overlooked infertility care should be part of national health services, says WHO
- German state railway loss widens, passengers warned of trouble ahead
- How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
